Cetera Investment Advisers
LTRN icon

Cetera Investment Advisers’s Lantern Pharma LTRN Stock Holding History

Cetera Investment Advisers’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51K Hold
12,228
– – ﹤0.01% 4767
2026
Q1 		$16.8K Hold
12,228
– – ﹤0.01% 4673
2025
Q4 		$37.1K Buy
+12,228
New +$45.5K ﹤0.01% 4540

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Cetera Investment Advisers's LTRN Position: Q2 2026 in Review

Cetera Investment Advisers held its Lantern Pharma (LTRN) position steady in Q2 2026 at 12,228 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #4767.

Cetera Investment Advisers first reported a position in LTRN in Q4 2025 and has held it in 3 quarters since. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Cetera Investment Advisers held 12,228 shares of Lantern Pharma worth $51K as of Q2 2026.
  • Cetera Investment Advisers left its Lantern Pharma share count unchanged in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4767 holding.
  • Cetera Investment Advisers first reported a position in Lantern Pharma in Q4 2025 and has held it in 3 quarters since.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.